Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429803 | 0.94 | RAB9A (0.38) | ALDH1A1RAB9AKDM4ENPC1LMNA | |
| SCHEMBL6500555 | 0.88 | L3MBTL1 (0.35) | ALDH1A1KMT2AKDM4EL3MBTL1MAPT | |
| SCHEMBL6499655 | 0.86 | ALDH1A1 (0.30) | ALDH1A1RAB9A | |
| SCHEMBL6510626 | 0.86 | TDP1 (0.34) | ALDH1A1RAB9AKMT2ALMNAHPGD | |
| SCHEMBL6508683 | 0.86 | SSTR3 (0.31) | — | |
| SCHEMBL6506173 | 0.84 | SMN1; SMN2 (0.37) | ALDH1A1RAB9AKMT2ANPC1LMNA | |
| SCHEMBL6505095 | 0.84 | KDM4E (0.32) | ALDH1A1KDM4EL3MBTL1MAPT | |
| SCHEMBL6499218 | 0.84 | LMNA (0.35) | ALDH1A1RAB9AKMT2AKDM4EL3MBTL1 | |
| SCHEMBL6501528 | 0.83 | L3MBTL1 (0.36) | RAB9AKDM4EL3MBTL1NPC1LMNA | |
| SCHEMBL6499622 | 0.83 | HPGD (0.35) | ALDH1A1RAB9AKMT2AL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | ALDH1A1 67/4885RAB9A 2649/4885KMT2A 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.